ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the 9th Annual Stem Cell Summit in New York. Dr. West will speak in the session Disrupting the Pharma Model with Allogeneic Stem Cell Therapies on February 18, 2014, starting at 9:05 a.m. EST.

Dr. West will discuss the potential comparative advantages of treating disease with BioTime's PureStem-based therapeutics compared to traditional small molecule pharmaceuticals and BioTime's product development strategy. The presentation will be made available on BioTime's website at http://www.biotimeinc.com.

About BioTime, Inc.

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTimes focus is on pluripotent stem cell technology based on human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTimes therapeutic and research products include a wide array of proprietary PureStem progenitors, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (a HyStem product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. In addition, BioTime has developed Hextend, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements.

BioTime is also developing stem cell and other products for research, therapeutic, and diagnostic use through its subsidiaries:

Asterias Biotherapeutics, Inc. is a new subsidiary which has acquired the stem cell assets of Geron Corporation, including patents and other intellectual property, biological materials, reagents and equipment for the development of new therapeutic products for regenerative medicine.

OncoCyte Corporation is developing products and technologies to diagnose and treat cancer.

Cell Cure Neurosciences Ltd. (Cell Cure Neurosciences) is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis.

LifeMap Sciences, Inc. (LifeMap Sciences) markets, sells and distributes GeneCards, the leading human gene database, as part of an integrated database suite that also includes the LifeMap Discovery database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database.

ES Cell International Pte Ltd., a Singapore private limited company, developed clinical and research grade hES cell lines and plans to market those cell lines and other BioTime research products in over-seas markets as part of BioTimes ESI BIO Division.

Continue reading here:
BioTime CEO Dr. Michael West to Present at 9th Annual Stem Cell Summit

Comments are closed.